XPO1 and breast cancer: Our results cannot exclude the possibility that the apparent effect of ISG12 on RFS in breast cancer patients could be associated to the dysregulation of the nuclear protein levels of yet to be identified tumor suppressors and other transcription factors whose nuclear export is mediated by the CRM/XPO1 system.